2010-2019年新西兰喘恶化:一项基于全国人口的研究
Amy Hai Yan Chan1, Andrew Tomlin1, Kebede Beyene2
1School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
Respiratory medicine
|July 22, 2023
概括
新西兰 (NZ) 的喘恶化率从2010年到2019年增加,特别是在女性,毛利人和太平洋人民中. 由于喘而入院的病例减少,这表明护理管理的转变.
科学领域:
- 公共卫生 公共卫生
- 流行病学 流行病学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 喘是全球普遍存在的慢性疾病,新西兰 (NZ) 患有高症状率.
- 关于新西兰的喘恶化趋势和人口统计学变化,有显著的数据差距.
- 了解这些趋势对于有效的公共卫生战略和喘管理至关重要.
研究的目的:
- 分析2010年至2019年新西兰国家喘恶化和住院率.
- 在不同的人口群体中调查喘恶化率的人口差异.
- 在研究期间确定喘护理管理的趋势.
主要方法:
- 一个回顾性,基于人口的观察性队列研究,利用来自五个国家医疗保健数据集的非识别数据.
- 这项研究持续了10年,从2010年到2019年.
- 喘恶化通过医院出院诊断或口服皮质类固醇发行记录来确定.
主要成果:
- 新西兰喘患者数量从2010年的447,797人增加到2019年的512,627人.
- 喘恶化的人口比率从2010年的每1000个患者年中的376.2上升到2019年的438.3.
- 恶化率在女性,毛利人和太平洋人群中始终较高,而住院病例总体下降了25%,但在毛利人和太平洋人群中仍然不成比例地高.
结论:
- 新西兰的喘恶化率在2010年至2019年之间呈现上升趋势.
- 相反,与喘相关的住院率在同一时期下降.
- 这些发现表明,在管理喘恶化时,可能会从二级医疗转向初级医疗,从而为未来的医疗保健计划提供信息.
相关概念视频
01:24Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
01:29Asthma-I: Introduction
2.7K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:20Asthma: Pathogenesis and Management
449
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
449
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
351
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
351